U.S. Markets for Obesity Drugs and Bariatric Surgical Devices

Countries covered: United States

Obesity is a global epidemic, afflicting more than 66 million people in the United States (U.S.) and an estimated 300 million people worldwide. Obesity directly contributes to several life-threatening conditions, including cardiovascular disease, cancer, diabetes, hypertension and stroke and costs for treating obesity in the U.S. surpass $120 billion.

This report discusses current and emerging anti-obesity drugs and bariatric surgical devices. In 2005, the U.S. market for obesity drugs and bariatric surgical devices was estimated at more than $350 million. This market is expected to grow at a compound annual rate of approximately 36%, reaching more than $1.6 billion in 2010.

While the obesity drug market has had a checkered history due to serious or unwanted side effects and several major product withdrawals, several new improved drugs are emerging that are expected to turn this segment into a significant growth market. Dozens of pharmaceutical companies have promising anti-obesity compounds under clinical trials and the competitive landscape will no doubt change dramatically over the coming decade. A blockbuster obesity drug—if proven safe and effective long-term—has the potential to achieve annual sales in excess of $1 billion. It is expected that one or more leading obesity drugs, including sanofi-aventis’ ACOMPLIA, will hit the market over the next five years.

Bariatric surgery—although typically reserved for the morbidly obese with no other options—is continuing rapid growth due to the increase in the obese population and increase in bariatric surgery advertising, surgeon training, insurance coverage, and public awareness. While gastric bypass comprised approximately 80% of all bariatric surgery procedures in 2005, gastric banding is expected to continue double-digit growth due to the popular LAP-BAND, as well as the introduction of competitive systems. In addition, less invasive intragastric balloons may serve as a “bridge” to bariatric surgery and new and emerging noninvasive weight loss devices are under development. Finally, less invasive gastric nerve stimulators, pioneered by Medtronic, are expected to be introduced on the market in 2008 and may initially achieve annual sales of more than $100 million.

This dynamic report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities. Covered topics in this report include: obesity drugs, gastroplasty, gastric bypass, gastric banding, intragastric balloons, general and laparoscopic surgical instruments, body contouring, gastric nerve stimulators and emerging noninvasive weight loss devices.

EXECUTIVE SUMMARY: i. Causes of Obesity; ii. Obesity as a Component of Metabolic Syndrome; iii. Obesity-Related Comorbidities; iv. Obesity Statistics; v. Emerging Obesity Drugs; vi. Obesity Drugs Market; vii. Bariatric Surgical Devices; viii. Bariatric Surgery Market; ix. Gastric Stimulators; x. Gastric Stimulators Market; xi. Total Obesity Drugs and Devices Market; xii. Methodology
1. CLINICAL AND STATISTICAL OVERVIEW: 1.1 Overview of the Digestive System; 1.2 Obesity Defined; 1.3 Causes of Obesity; 1.4 Obesity-Related Comorbidities; 1.5 Obesity Statistics; 1.6 Economic Impact; 1.7 Treatment and Prevention; 1.8 Medicare Coverage; 1.9 Societal and Legal Issues
2. OBESITY DRUGS MARKET: 2.1 Drug Safety and Efficacy; 2.2 Regulatory Approval Process; 2.3 Insurance Reimbursement; 2.4 Current Obesity Drugs; 2.5 Emerging Drugs; 2.6 Alternative Therapies; 2.7 Market Analysis; 2.8 Competitive Analysis
3. BARIATRIC SURGERY MARKET: 3.1 Surgical Risks; 3.2 Efficacy; 3.3 Regulatory Approval Process; 3.4 Insurance Reimbursement; 3.5 Bariatric Surgery; 3.6 Body Contouring; 3.7 General and Laparoscopic Surgical Instruments; 3.8 Market Analysis; 3.9 Competitive Analysis
4. GASTRIC STIMULATORS MARKET: 4.1 Methods of Gastric Stimulation; 4.2 Safety; 4.3 Efficacy; 4.4 Insurance Reimbursement; 4.5 Regulatory Approval Process; 4.6 Current and Emerging Gastric Stimulators; 4.7 Market Analysis; 4.8 Competitive Analysis
5. COMPANY PROFILES: 5.1 Abbott Laboratories; 5.2 Arena Pharmaceuticals, Inc.; 5.3 BaroNova, Inc.; 5.4 BaroSense, Inc.; 5.5 Cyberonics, Inc.; 5.6 EndoArt SA; 5.7 EnteroMedics, Inc.; 5.8 Ethicon Endo-Surgery/Johnson & Johnson; 5.9 GlaxoSmithkline PLC; 5.10 Hélioscopie SA; 5.11 Inamed Corporation/Allergan, Inc.; 5.12 IntraPace, Inc.; 5.13 Leptos Biomedical, Inc.; 5.14 Medtronic, Inc.; 5.15 Merck & Company, Inc.; 5.16 MetaCure NV; 5.17 Pfizer, Inc.; 5.18 F. Hoffmann La-Roche LTD/Roche Group; 5.19 Sanofi-Aventis; 5.20 Satiety, Inc.; 5.21 Scientific Intake; 5.22 VIVUS, Inc.
APPENDIX: COMPANY LISTING